{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:20:01Z","timestamp":1769923201987,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.4158\/ep11194.or","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T21:15:19Z","timestamp":1320786919000},"page":"342-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and \u03b2-Cell Dysfunction"],"prefix":"10.1016","volume":"18","author":[{"given":"John","family":"Armato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Abdul-Ghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Ruby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP11194.OR_bb0010","unstructured":"Centers for Disease Control. Number of people with diabetes increases to nearly 26 million. Available at: http:\/\/www.cdc.gov\/features\/diabetesfactsheet\/"},{"key":"10.4158\/EP11194.OR_bb0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diabres.2007.05.004","article-title":"Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies","volume":"78","author":"Gerstein","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.4158\/EP11194.OR_bb0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.1464-5491.2002.00835.x","article-title":"Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention","volume":"19","author":"Unwin","year":"2002","journal-title":"Diabet Med"},{"key":"10.4158\/EP11194.OR_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/diacare.22.3.399","article-title":"Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?","volume":"22","author":"Shaw","year":"1999","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0030","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2337\/diacare.23.8.1113","article-title":"Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes","volume":"23","author":"Gabir","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11892-008-0030-1","article-title":"Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus","volume":"8","author":"Abdul-Ghani","year":"2008","journal-title":"Curr Diab Rep"},{"key":"10.4158\/EP11194.OR_bb0040","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2337\/dc06-1331","article-title":"What is the best predictor of future type 2 diabetes?","volume":"30","author":"Abdul-Ghani","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.24.1.89","article-title":"Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development","volume":"24","author":"Weyer","year":"2001","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diabetes.54.1.166","article-title":"Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes","volume":"54","author":"Lyssenko","year":"2005","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0055","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(89)92804-3","article-title":"Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes","volume":"1","author":"Saad","year":"1989","journal-title":"Lancet"},{"key":"10.4158\/EP11194.OR_bb0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2337\/diabetes.55.04.06.db05-1100","article-title":"The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study","volume":"55","author":"Festa","year":"2006","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0065","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/dmrr.1084","article-title":"The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes","volume":"26","author":"Abdul-Ghani","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.4158\/EP11194.OR_bb0075","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/dc05-2179","article-title":"Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11194.OR_bb0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","article-title":"Impaired fasting glucose and impaired glucose tolerance: implications for care","volume":"30","author":"Nathan","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4158\/EP11194.OR_bb0100","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"54","author":"Knowler","year":"2005","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0105","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0110","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators","year":"2006","journal-title":"Lancet"},{"key":"10.4158\/EP11194.OR_bb0115","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"key":"10.4158\/EP11194.OR_bb0120","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolereance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/EP11194.OR_bb0125","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4158\/EP11194.OR_bb0130","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2009-0911","article-title":"Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus","volume":"95","author":"Bajaj","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11194.OR_bb0135","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.4158\/EP11194.OR_bb0140","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1152\/ajpendo.00551.2006","article-title":"Thiazolidinediones improve beta-cell function in type 2 diabetic patients","volume":"292","author":"Gastaldelli","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP11194.OR_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/17446651.1.3.329","article-title":"Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"1","author":"Triplitt","year":"2006","journal-title":"Expert Rev Endocr Metab"},{"key":"10.4158\/EP11194.OR_bb0150","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0155","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0160","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/EP11194.OR_bb0165","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0170","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.2337\/dc07-0422","article-title":"The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects","volume":"30","author":"Anderwald","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0175","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.4158\/EP11194.OR_bb0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.4158\/EP11194.OR_bb0185","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP11194.OR_bb0190","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP11194.OR_bb0195","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus","volume":"81","author":"Cusi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11194.OR_bb0200","first-page":"89","article-title":"Metformin: a review of its metabolic effects","volume":"6","author":"Cusi","year":"1998","journal-title":"Diabetes Rev"},{"key":"10.4158\/EP11194.OR_bb0205","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"10.4158\/EP11194.OR_bb0210","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP11194.OR_bb0215","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W","article-title":"UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group","volume":"15","author":"Matthews","year":"1998","journal-title":"Diabet Med"},{"key":"10.4158\/EP11194.OR_bb0225","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0230","first-page":"221","article-title":"Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men","volume":"49","author":"Shalev","year":"1998","journal-title":"Horm Res"},{"key":"10.4158\/EP11194.OR_bb0235","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/ijo.2008.134","article-title":"First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes","volume":"32","author":"Venditti","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"10.4158\/EP11194.OR_bb0240","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.2337\/dc10-0410","article-title":"Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D)","volume":"33","author":"Saaristo","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11194.OR_bb0245","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20414569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20414569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/K6L1360H75K91643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:53:39Z","timestamp":1761515619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20414569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1530891X20414569"],"URL":"https:\/\/doi.org\/10.4158\/ep11194.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and \u03b2-Cell Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP11194.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}